Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer - PubMed (original) (raw)
Affiliations
- PMID: 11234881
Comparative Study
Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer
Y Niwa et al. Clin Cancer Res. 2001 Feb.
Abstract
The beta-chemokine RANTES was measured in plasma in 43 patients with breast cancer and in 23 patients with cervical cancer, and the RANTES content in primary tumors, tumor metastatic to lymph nodes, and clinically normal skin or pelvic mucosa was measured. In addition, plasma levels were determined in all of the patients for the platelet-derived chemokine beta-thromboglobulin (beta-TG) and for IFN-gamma, interleukin (IL)-2, IL-4, IL-5, and IL-10, along with serum IgE levels and blood eosinophils. Plasma RANTES levels were found to be higher in order of stages IV, III, II, and I of each cancer except for stage I. A marked increase in plasma RANTES level (> 10,000 pg/ml) was found in 27% of patients with progressive malignancy but in none of those in clinical remission. The platelet RANTES content was correspondingly decreased in those patients with increased plasma RANTES levels. Beta-TG showed a pattern similar to RANTES both in plasma and platelets, but with much less dramatic differences between patients with different stages of disease. Other allergic parameters, IgE, eosinophils and plasma IFN-gamma, IL-2, -5, and -10, were not elevated in the cancer patients. The RANTES content was markedly elevated in the primary tumor and metastatic lesions (lymph node or skin) from all of the patients with breast or cervical cancer, irrespective of the plasma RANTES level. In addition, in patients with progressive breast or cervical cancer, but not in patients thought to be cured of these tumors, the RANTES content was markedly increased in clinically normal tissue taken from near the operative site several months postoperatively, as well as in intact skin or mucosa taken perioperatively near the excised tumor. This study suggests an as-yet-undefined but important role played by RANTES in carcinogenesis, as well as the possibility that a RANTES assay in tissue surrounding a tumor or postoperative tumor site may help predict prognosis in these patients.
Similar articles
- Modulatory roles of RANTES in IL-4 production by human blood CD4(+)T cells.
Saito S, Yamaguchi E, Nakayama H, Miyamoto K, Kawakami Y. Saito S, et al. Cytokine. 2000 Sep;12(9):1380-4. doi: 10.1006/cyto.2000.0736. Cytokine. 2000. PMID: 10975998 - Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma.
Romero JM, Aptsiauri N, Vazquez F, Cozar JM, Canton J, Cabrera T, Tallada M, Garrido F, Ruiz-Cabello F. Romero JM, et al. Tissue Antigens. 2006 Oct;68(4):303-10. doi: 10.1111/j.1399-0039.2006.00673.x. Tissue Antigens. 2006. PMID: 17026465 - Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines.
Giustizieri ML, Mascia F, Frezzolini A, De Pità O, Chinni LM, Giannetti A, Girolomoni G, Pastore S. Giustizieri ML, et al. J Allergy Clin Immunol. 2001 May;107(5):871-7. doi: 10.1067/mai.2001.114707. J Allergy Clin Immunol. 2001. PMID: 11344355 - The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity.
Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, Wigler N, Keydar I, Ben-Baruch A. Azenshtein E, et al. Cancer Res. 2002 Feb 15;62(4):1093-102. Cancer Res. 2002. PMID: 11861388 - Low levels of RANTES are associated with mortality in children with cerebral malaria.
John CC, Opika-Opoka R, Byarugaba J, Idro R, Boivin MJ. John CC, et al. J Infect Dis. 2006 Sep 15;194(6):837-45. doi: 10.1086/506623. Epub 2006 Aug 16. J Infect Dis. 2006. PMID: 16941352
Cited by
- Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs.
Umekawa K, Kimura T, Kudoh S, Suzumura T, Oka T, Nagata M, Mitsuoka S, Matsuura K, Nakai T, Yoshimura N, Kira Y, Hirata K. Umekawa K, et al. BMC Res Notes. 2013 Apr 8;6:139. doi: 10.1186/1756-0500-6-139. BMC Res Notes. 2013. PMID: 23566546 Free PMC article. - CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma.
Cambien B, Richard-Fiardo P, Karimdjee BF, Martini V, Ferrua B, Pitard B, Schmid-Antomarchi H, Schmid-Alliana A. Cambien B, et al. PLoS One. 2011;6(12):e28842. doi: 10.1371/journal.pone.0028842. Epub 2011 Dec 20. PLoS One. 2011. PMID: 22205974 Free PMC article. - CCL5 protein level: influence on breast cancer staging and lymph nodes commitment.
Derossi DR, Amarante MK, Guembarovski RL, de Oliveira CEC, Suzuki KM, Watanabe MAE, de Syllos Cólus IM. Derossi DR, et al. Mol Biol Rep. 2019 Dec;46(6):6165-6170. doi: 10.1007/s11033-019-05051-8. Epub 2019 Nov 5. Mol Biol Rep. 2019. PMID: 31691056 - Three-Dimensional Breast Cancer Model to Investigate CCL5/CCR1 Expression Mediated by Direct Contact between Breast Cancer Cells and Adipose-Derived Stromal Cells or Adipocytes.
Watzling M, Klaus L, Weidemeier T, Horder H, Ebert R, Blunk T, Bauer-Kreisel P. Watzling M, et al. Cancers (Basel). 2023 Jul 5;15(13):3501. doi: 10.3390/cancers15133501. Cancers (Basel). 2023. PMID: 37444610 Free PMC article. - RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cells.
Gallo M, Frezzetti D, Roma C, Chicchinelli N, Barbieri A, Arra C, Scognamiglio G, Botti G, De Luca A, Normanno N. Gallo M, et al. Oncotarget. 2018 Apr 3;9(25):17543-17553. doi: 10.18632/oncotarget.24784. eCollection 2018 Apr 3. Oncotarget. 2018. PMID: 29707128 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous